Monday, November 18, 2024
- 10:30AM-12:30PM
-
Abstract Number: 2423
Associations Between Cytometric Interferon Signature and Clinical Response in a Cohort of Anifrolumab-treated Patients with Lupus
SLE – Treatment Poster III- 10:30AM-12:30PM
-
Abstract Number: 2241
Associations Between Disease Activity, Physical Function and Anti-rheumatic Medications with All-cause Mortality in Rheumatoid Arthritis (RA): Data from a Canadian RA Registry
RA – Diagnosis, Manifestations, & Outcomes Poster III- 10:30AM-12:30PM
-
Abstract Number: 2061
Associations Between Intramyocellular Lipid and Muscle Function in Patients with Osteoarthritis
Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III- 10:30AM-12:30PM
-
Abstract Number: 2289
Associations Between Protein Quantitative Trait Loci and Risk of Primary Sjögren’s Syndrome: A Mendelian Randomization Study
Sjögren's Syndrome – Basic & Clinical Science Poster II- 10:30AM-12:30PM
-
Abstract Number: 2411
Attainment of Complete Renal Response in Patients with Active Lupus Nephritis: A Multi-Center Cohort Study
SLE – Diagnosis, Manifestations, & Outcomes Poster III- 10:30AM-12:30PM
-
Abstract Number: 2435
Attainment of Remission, Use of Immunomodulatory/suppressive Agents and Gradual Dose Tapering May Facilitate Flare-free Withdrawal of Glucocorticoids in Patients with Systemic Lupus Erythematosus
SLE – Treatment Poster III- 10:30AM-12:30PM
-
Abstract Number: 2468
Audio-Guided Imagery Positively Impacted Patients with Raynaud’s Phenomenon Associated Connective Tissue Disease
Systemic Sclerosis & Related Disorders – Clinical Poster III- 10:30AM-12:30PM
-
Abstract Number: 1876
Automated Case Identification of Patients with End-Stage Renal Disease and Systemic Lupus Erythematosus Using Machine Learning
Epidemiology & Public Health Poster III- 10:30AM-12:30PM
-
Abstract Number: 2025
Autonomic Nervous System Dysfunction Common Among Patients with Long COVID:Diagnosis and Treatment Implications
Miscellaneous Rheumatic & Inflammatory Diseases Poster III- 10:30AM-12:30PM
-
Abstract Number: 2489
Avacopan for Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) in a Real-World Setting
Vasculitis – ANCA-Associated Poster III- 10:30AM-12:30PM
-
Abstract Number: 2480
Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis and Ear, Nose, or Throat Involvement in a Phase 3 Trial
Vasculitis – ANCA-Associated Poster III- 10:30AM-12:30PM
-
Abstract Number: 2478
Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis Without Kidney Involvement in a Phase 3 Trial
Vasculitis – ANCA-Associated Poster III